NMS·Healthcare·$155M·#257 / 520 in Healthcare
BDTX Black Diamond Therapeutics, Inc
43SPECULATIVE
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY96
VALUATION94
GOVERNANCE34
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
N/A
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
16.7%
87
< 25% strong
Price / Sales
Market cap relative to trailing revenue
2.2x
94
< 3x strong
Rule of 40
Growth rate plus operating margin
N/A
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.6%
5
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+1.1%
93
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE BDTX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when BDTX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.